Atty Docket No. 20695C-005900US

PTO FAX NO.:

703.872.9306

ATTENTION:

Examiner Haddad, Maher M.

TELEPHONE NO.:

703.306.3472

Group Art Unit 1644

OFFICIAL COMMUNICATION

FOR THE PERSONAL ATTENTION OF

RECEIVED CENTRAL FAX CENTER

DECA

OCT 0 9 2003

EXAMINER Haddad, Maher M

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following document(s) in re Application of SCHEIFLINGER et al., Application No. 09/661,992, filed September 14, 2000 for FACTOR IX/FACTOR IXA ACTIVATING ANTIBODIES AND ANTIBODY DERIVATIVES is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Document(s) Attached

- 1. Transmittal Form
- 2. Fee Transmittal
- 3. Petition for Extension of Time Under 37 CFR 1.136(a)
- 4. Preliminary Amendment and Response to Restriction Requirement (8 pages)

Number of pages being transmitted, including this page: 12

Dated: October 8, 2003

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (303) 571-4321

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111-3834 Telephone: 303-571-4000 Fax: 303-571-4321

60056126 v1

PTO/SB/21 (08-03)

	·	Application Number	00/884 002	Part form 9 16 5"	A K		
TRANSMITTAL	_	Application Number	09/661,992		11/1		
FORM	-	Filing Date	September 14, 2000	71116	' 16		
	. (W.a.) 400a.s	First Named Inventor	Scheiflinger, Friedrich	RECEIVE	En		
(to be used for all correspondence after	iniuai filing)	Art Unit	1644 CE	NTRAL FAX			
		Examiner Name	Haddad, Maher M	~~~~ ~ ~ ~	KARE		
Total Number of Pages in This Submission		Attorney Docket Number	20695C-005900US	UCI 0 9 2	ZUU3		
	ENC	LOSURES (Check all that ap)	(y)				
Fee Transmittal Form		ng(s)	After Allowance Communication	to Group			
Fee Attached	Licens	ing-related Papers	Appeal Communication to Board and Interferences	of Appeals			
Amendment/Reply	Petition	n .	Appeal Communication to Group Notice, Brief, Reply Brief)) (Appeal			
After Final		n to Convert to a ional Application	Proprietary Information				
Affidavits/declaration(s)	Power Chang	of Attorney, Revocation e of Correspondence Address	Status Letter				
Extension of Time Request	Termir	nal Disclaimer	Other Enclosure(s) (please identify below):				
Express Abandonment Request		st for Refund		ļ			
		umber of CD(s)					
Information Disclosure Statement							
Certified Copy of Priority Document(s)	Rema		authorized to charge any additional fee:	s to Deposit			
Response to Missing Parts/ Incomplete Application							
Response to Missing Parts under 37 CFR 1.52 or 1.53							
		F APPLICANT, ATTORNE	, OR AGENT				
Firm Townsend and or							
Individual Scott L Auseni	nus	Reg. No. 42,271					
Signature of	lueis	dul					
Date October 8, 200	3		<u> </u>	<u> </u>			
		ERTIFICATE OF MAILING		三			
I hereby certify that this correspondence October 8, 2003.			d Trademark Office, Fax No. (703) 872-	3306 on			
Typed or printed name Tara N. Dan	nhoff		0				
Signature	N	Da-1-4	Date October 8, 2003				
- / //	/ - '	1	<u> </u>				

·						PTO/SB/17 (10-03)
EEE TO ANICHAITTAL				Co	mplete if Knov	vn	
FEE TRANSMITTAL	Application Number 09/661,992						
for FY 2004	Filing Date September 14, 2000			00			
Effective 10/01/2003. Patent lees are subject to annual revision.	First Na	First Named Inventor Scheiflinger, Friedrich			lri <u>ch</u>		
Applicant claims small entity status. See 37 CFR 1.27	Exeminer Name Haddad, Maher M						
	Art Unit 1644						
TOTAL AMOUNT OF PAYMENT (S) 110	Attorney Docket No. 20695C-005900US						
	711207110					45 (40)	
METHOD OF PAYMENT (check all that apply)	3. ADD	TIONAL	FEES	FEE C	ALCULATION (cor	mnuea)	
Check Credit Card Money Order Other Mone	Large	Entity	Smali	Enlity			
Deposit Account:	Fee	Fee	Fee	Foo	Fee De	scription	Fee
Deposit Account 20-1430	Code 1051	(\$) 130	Code 2051	(\$) 65	Surcharge - late f	•	Paid
Number	1052	50	2052	25	-	rovisional filing fee	
Account Townsend and Townsend and Crew LLP	1053	130	1053	130	Non-English spec		
Name	1812 1804	2,520 920*	1812 1804	2,520 920"		st for reexamination cation of SIR prior to	
The Director is authorized to: (check all that apply) Charge fee(s) indicated below Credit any overpayments	1007	727	1004		Examiner action	· · · · · · · · · · · · · · · · · · ·	
Charge any additional fee(s) or any underpayment of fee(s)	1805	1,8401	1805	1.840*	Requesting public Examiner action	sation of SIR after	
Charge fea(s) indicated below, except for the filing fee	1251	110	2251	55	•	y within first month	110
to the above-idemified deposit socount	1252	420	2252	210	Extension for repl month	y within second	
	1253	950	2253	475		y within third month	
1. BASIC FILING FEE Large Entity Small Entity	1254	1,480	2254	740	Extension for replinership	ly within fourth	
Fee Fee Fee Fee Description Fee Pald	1255	2.010	2255	1,005		ly within fifth month	
Code (\$) Code (\$) 1001 770 2001 385 Utility filing fee	1401	330	2401	165	Notice of Appeal		
1002 340 2002 170 Design filling fee	1402	330 290	2402 2403	165 145	Filing a brief in su Request for oral t	pport of an appeal	
1003 530 2003 265 Plant flling fee	1451	1,510	1451	1,510	Pelition to institut	_	
1004 770 2004 385 Relatue filing fee		•	l .	-	proceeding		
1005 160 2005 80 Provisional filing fee	1452 1453	110 1,330	2452 2453	55 655	Petition to revive		
SUBTOTAL (1) (\$)0	1501	1,330	2501	855	Utility Issue fee (or reissue)		
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1502	480	2502	240			
Fee from	1503	640	2503	320	Plant Issue fee		<u> </u>
Extra Claims below Fee Paid	1460 1607	130 50	1460 1807	130 50	Petitions to the C Petitions related t		
Total Claims 22 -24*** = 0 X318 * \$0					applications	•	
Independent 2 -3** = 0 X\$586 = \$0	1808	180	1906	190	Submission of Inf	ormation Disclosure	
Multiple Dependent X =	8021	40	6021	40	Recording each p per property (time properties)	patent assignment as number of	
Large Entity Small Entity	1809	770	2809	385	Filing a aubmissio	on alter final rejection	
Fee Fee Fee Fee Fee Description	1610	770	2810	365	(37 CFR § 1,129) For each addition	a)) al invention to be	
1202 16 2202 9 Claims in excess of 20					examined (37 CF	R § 1.129(b))	
1201 86 2201 43 Independent claims in excess of 3	1801	770	2801	385	Request for Cont (RCE)	nued Examination	1
1203 290 2203 145 Multiple dependent clalm, if not paid 1204 86 2204 43 "Relasue independent chalms over original patent	1802	900	1802	900	•	noitenlmake batib noites	
1205 18 2205 9 Reissue claims in excess of 20 and over original patent	Other fee (specify)						
SUBTOTAL (2) (5)0 "or number previously paid, if greater; For Reissues, see above	*Reduced by Basic Filling Fee Pald SUBTOTAL (3) (\$)110						
SUBMITTED BY Complete (if applicable)							
Name (Print/Type) Scott - Auser)Not Registration No. (Attern	ey/Agent)	42	,271		Telephone	303-571-4000	
Signature soft when we					Date	October 6, 2003	

WARNING: Information on this term may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2036.

PTO/SB/22 (08-03)

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)						Docket Number (Optional) 20695C-005900US				
			In re Ap	olication of SC	HEIFLINGE	R et al.				
			Application Number 09/661,992			Filed September 14, 2000				
				ACTOR IX/FAC	CTOR IXA A	ACTIVATING ANTIBODIES AND ANTIBODY				
	•		Art Unit	1644	E	xaminer Haddad, Maher M				
This is a r applicatio		t under the provisions	of 37 CFF	t 1.136(a) to ex	dend the pe	ariod for filing a reply in the above identified				
The requi	ested e	xtension and appropri	ate non-si	nall-entity fee	are as follow	vs (check time period desired):				
·	\boxtimes	One month (37 CFR	1.17(a)(1))		\$110				
	☐ Two months (37 CFR 1.17(a)(2))			2))		\$				
ı		☐ Three months (37 CFR 1.17(a)(3))				\$				
,	☐ Four months (37 CFR 1.17(a)(4))					\$				
		Five months (37 CF	R 1.17(a)(5))	-	\$				
		cant claims small entit ie-half, and the resulti			.27. Therefo	ore, the fee amount shown above is reduced				
	A check in the amount of the fee is enclosed.									
	Payment by credit card. Form PTO-2038 is attached.									
	The D	Director has already be	en autho	rized to charge	fees in this	application to a Deposit Account.				
×		Director is hereby auth sit Account Number 2		charge any fee	s which may	y be required, or credit any overpayment, to				
	i have	e enclosed a duplicate	copy of ti	nis sheet.						
I am th	ie 🔲	applicant/invento	r.							
		assignee of record of Statement unde								
	attorney or agent of record Registration Number 42,271									
	attorney or agent under 37 CFR 1.34(a).									
		Registration number if ac	ting under 3	7 CFR 1.34(a)	<u> </u>					
		Information on this in. Provide credit car				p PTO-2038.				
***		October 8, 2003			100	th Churchalul				
		Date				Signature				
						Scott L. Ausenhus, Reg. No. 42,271				
						Typed or printed name				
		all the inventors or assigned required, see below*.	s of record o	f lhe entira interes	t or their repres	entative(s) are required. Submit multiple forms if more				
Ustoll*		forms are submitted.								

60056105 v1

I hereby certify that this correspondence is being factimile transmitted to the United States Patent and Trademark Office, Fax No. 703-872-9306 on October 8, 2003.

20695C-005900US <u>PATENT</u>

TOWNSEND and TOWNSEND and CREW LLP

Tora N. Damboff

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHEIFLINGER et al.

Application No.: 09/661,992

Filed: September 14, 2000

For: FACTOR IX/FACTOR IXA ACTIVATING ANTIBODIES AND ANTIBODY DERIVATIVES

Customer No.: 20350

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Confirmation No.: 8902

Examiner: Haddad, Maher M

Technology Center/Art Unit: 1644

PRELIMINARY AMENDMENT AND RESPONSE TO RESTRICTION

REQUIREMENT

Sir:

This paper is filed in response to the Restriction Requirement mailed August 26, 2003. The original deadline for filing a response was September 26, 2003. A petition for a one month extension of time is enclosed, thus extending the deadline until October 26, 2003. Accordingly, this response is timely filed.

Applicants request consideration of the following amendments and remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.